Journal of Antimicrobial Chemotherapy, Vol 40, 717-720, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
M Lecso-Bornet and E Bergogne-Berezin
One hundred clinical strains of Stenotrophomonas maltophilia were
investigated for their susceptibility to ticarcillin, piperacillin,
ceftazidime and five combinations with beta-lactamase inhibitors
(clavulanic acid, tazocillin or sulbactam) at three concentrations; 26% of
the strains were susceptible to ticarcillin, 23% to ceftazidime and 12% to
piperacillin. Eighty-two percent of the strains were susceptible to
ticarcillin/clavulanic acid. In most cases, no synergy was observed with
tazobactam or sulbactam. For eight ticarcillin-susceptible strains,
antagonism was observed between ticarcillin and clavulanic acid.
ORIGINAL ARTICLES
Susceptibility of 100 strains of Stenotrophomonas maltophilia to three beta-lactams and five beta-lactam-beta-lactamase inhibitor combinations
Department of Microbiology, X. Bichat-Claude Bernard University Hospital, Paris, France.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Valdezate, A. Vindel, E. Loza, F. Baquero, and R. Cantón Antimicrobial Susceptibilities of Unique Stenotrophomonas maltophilia Clinical Strains Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1581 - 1584. [Abstract] [Full Text] |
||||
![]() |
F.-J. Schmitz, R. Sadurski, J. Verhoef, D. Milatovic, and A. C. Fluit Typing of 154 clinical isolates of Stenotrophomonas maltophilia by pulsed-field gel electrophoresis and determination of the in vitro susceptibilities of these strains to 28 antibiotics J. Antimicrob. Chemother., June 1, 2000; 45(6): 921 - 923. [Full Text] [PDF] |
||||

